New study aims to improve breast cancer treatment before surgery
NCT ID NCT07523789
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looks back at data from 201 people with triple-negative breast cancer who received chemotherapy or immunotherapy before surgery. The goal is to compare how often the cancer completely disappears after treatment and find out what factors influence success. This is an observational study, not a test of a new drug, so it helps doctors learn which treatments work best for this aggressive cancer.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TNBC - TRIPLE-NEGATIVE BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
the First Affiliated Hospital of Nanjing Medical University
Nanjing, Jiangsu, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can Gene-Edited immune cells tame Hard-to-Treat cancers?
- Can a One-Time Anti-Inflammatory shot during surgery curb Triple-Negative breast Cancer's return?
- Triple-Drug cocktail aims to stall aggressive breast cancer
- Could a vaccine stop Triple-Negative breast cancer from coming back?
- Engineered immune cells take aim at Mesothelin-Positive tumors
- New imaging tracer could spot hidden cancers